Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5

Genes and Immunity

Volumn 6, Issue 7, 2005, Pages 609-619

  Dong, H F ^a   Wigmore, K ^a,e   Carrington, M N ^a   Dean, M ^b   Turpin, J A ^c,f   Howard, O M Z ^d  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CCR5; Chemokine receptor; Desentization; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING ASSAY; CELL STRAIN HEK293; CELL SURFACE; CHEMOTAXIS; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SPACE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN VARIANT;

ALLELES; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CALCIUM SIGNALING; CELL LINE; CHEMOKINES, CC; CHEMOTAXIS; HIV-1; HUMANS; LIGANDS; MACROPHAGE INFLAMMATORY PROTEIN-1; MOLECULAR SEQUENCE DATA; MUTATION; RANTES; RECEPTORS, CCR5; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 27844457605     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364247     Document Type: Article

References (63)

1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 1996; 272: 872-877.
2. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9: 551-562.
3. Littman DR. Chemokine receptors: Keys to AIDS pathogenesis? Cell 1998; 93: 677-680.
4. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996; 271: 17161-17166.
5. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
6. Gong W, Howard OM, Turpin JA et al. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J Biol Chem 1998; 273: 4289-4292.
7. Ruffing N, Sullivan N, Sharmeen L, Sodroski J, Wu L. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 1998; 189: 160-168.
8. Mackay CR. CCL3L1 dose and HIV-1 susceptibility. Trends Mol Med 2005; 11: 203-206.
9. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307: 1434-1440.
10. Struyf S, Menten P, Lenaerts JP et al. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur J Immunol 2001; 31: 2170-2178.
11. Howard OM, Turpin JA, Goldman R, Modi WS. Functional redundancy of the human CCL4 and CCL4L1 chemokine genes. Biochem Biophys Res Commun 2004; 320: 927-931.
12. Zagury D, Lachgar A, Chams V et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95: 3857-3861.
13. 2+ in regulation of IL-1beta secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. Am J Physiol Cell Physiol 2003; 285: C286-C299.
14. Murphy PM, Baggiolini M, Charo IF et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176.
15. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
16. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study [see comments] [published erratum appears in Science 1996 Nov 15;274(5290):1069]. Science 1996; 273: 1856-1862.
17. Blanpain C, Lee B, Tackoen M et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2000; 96: 1638-1645.
18. Howard OM, Shirakawa AK, Turpin JA et al. Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function. J Biol Chem 1999; 274: 16228-16234.
19. Zimmerman PA, Buckler-White A, Alkhatib G et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3: 23-36.
20. Dean M, Jacobson LP, McFarlane G et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59: 3561-3564.
21. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93: 1838-1842.
22. Barcellos LF, Schito AM, Rimmler JB et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 2000; 51: 281-288.
23. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102: 98-106.
24. Zang YC, Samanta AK, Halder JB et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 2000; 123 (Part 9): 1874-1882.
25. Gomez-Reino JJ, Pablos JL, Carreira PE et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42: 989-992.
26. Garred P, Madsen HO, Petersen J et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25: 1462-1465.
27. Herfarth H, Pollok-Kopp B, Goke M, Press A, Oppermann M. Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease. Immunol Lett 2001; 77: 113-117.
28. Petrek M, Drabek J, Kolek V et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162 (Part 1): 1000-1003.
29. Eri R, Jonsson JR, Pandeya N et al. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004; 5: 444-450.
30. Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U. CC-chemokine receptor 5 (CCR5) in hepatitis C - at the crossroads of the antiviral immune response? J Antimicrob Chemother 2004; 53: 895-898.
31. Andres PG, Beck PL, Mizoguchi E et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: Lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164: 6303-6312.
32. Nansen A, Christensen JP, Andreasen SO, Bartholdy C, Christensen JE, Thomsen AR. The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002; 99: 1237-1245.
33. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 2000; 156: 1951-1959.
34. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997; 61: 1261-1267.
35. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997; 16: 221-222.
36. Rabut GE, Konner JA, Kajumo F, Moore JP, Dragic T. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 3464-3468.
37. Dragic T, Trkola A, Lin SW et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998; 72: 279-285.
38. Blanpain C, Lee B, Vakili J et al. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 1999; 274: 18902-18908.
39. Zhao XY, Lee SS, Wong KH et al. A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor. AIDS 2004; 18: 1729-1732.
40. Howard OM, Korte T, Tarasova NI et al. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukocyte Biol 1998; 64: 6-13.
41. Chabot DJ, Chen H, Dimitrov DS, Broder CC. N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol 2000; 74: 4404-4413.
42. Signoret N, Christophe T, Oppermann M, Marsh M. pH-independent endocytic cycling of the chemokine receptor CCR5. Traffic 2004; 5: 529-543.
43. Signoret N, Hewlett L, Wavre S, Pelchen-Matthews A, Oppermann M, Marsh M. Agonist-induced endocytosis of chemokine receptor 5 (CCR5) is clathrin-dependent. Mol Biol Cell 2005; 16: 902-917.
44. Chelli M, Alizon M. Rescue of HIV-1 receptor function through cooperation between different forms of the CCR5 chemokine receptor. J Biol Chem 2002; 277: 39388-39396.
45. Shioda T, Nakayama EE, Tanaka Y et al. Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol 2001; 75: 3462-3468.
46. Kraft K, Olbrich H, Majoul I, Mack M, Proudfoot A, Oppermann M. Characterization of sequence determinants within the carboxyl-terminal domain of chemokine receptor CCR5 that regulate signaling and receptor internalization. J Biol Chem 2001; 276: 34408-34418.
47. Venkatesan S, Petrovic A, Locati M, Kim YO, Weissman D, Murphy PM. A membrane-proximal basic domain and cysteine cluster in the C-terminal tail of CCR5 constitute a bipartite motif critical for cell surface expression. J Biol Chem 2001; 276: 40133-40145.
48. Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 2002; 277: 17291-17299.
49. Paterlini MG. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J 2002; 83: 3012-3031.
50. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, Owman C. Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS 2003; 17: 2571-2579.
51. McDermott DH, Beecroft MJ, Kleeberger CA et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000; 14: 2671-2678.
52. Gonzalez E, Dhanda R, Bamshad M et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001; 98: 5199-5204.
53. Youn BS, Yu KY, Alkhatib G, Kwon BS. The seventh transmembrane domain of cc chemokine receptor 5 is critical for MIP-1beta binding and receptor activation: Role of MET 287. Biochem Biophys Res Commun 2001; 281: 627-633.
54. Tsamis F, Gavrilov S, Kajumo F et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77: 5201-5208.
55. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
56. Liao F, Alderson R, Su J, Ullrich SJ, Kreider BL, Farber JM. STRL22 is a receptor for the CC chemokine MIP-3alpha. Biochem Biophys Res Commun 1997; 236: 212-217.
57. Mueller A, Kelly E, Strange PG. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 2002; 99: 785-791.
58. Roland J, Murphy BJ, Ahr B et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 2003; 101: 399-406.
59. Lillard Jr JW, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 2003; 101: 807-814.
60. Dairaghi DJ, Franz-Bacon K, Callas E et al. Macrophage inflammatory protein-1beta induces migration and activation of human thymocytes. Blood 1998; 91: 2905-2913.
61. Pollok-Kopp B, Schwarze K, Baradari VK, Oppermann M. Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies. J Biol Chem 2003; 278: 2190-2198.
62. Howard OM, Kirken RA, Garcia GG, Hackett RH, Farrar WL. Structural domains of interleukin-2 receptor beta critical for signal transduction: kinase association and nuclear complex-formation. Biochem J 1995; 306: 217-224.
63. Zack JA, Arrigo SJ, Weissman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-222.